{"id":35828,"date":"2025-08-06T17:33:35","date_gmt":"2025-08-06T21:33:35","guid":{"rendered":"https:\/\/www.cancerresearch.org\/?post_type=cri_scientists&#038;p=35828"},"modified":"2025-08-06T17:33:42","modified_gmt":"2025-08-06T21:33:42","slug":"rachael-safyan-md","status":"publish","type":"cri_scientists","link":"https:\/\/www.cancerresearch.org\/es\/cri-funded-scientists\/rachael-safyan-md","title":{"rendered":"Rachael Safyan, MD"},"content":{"rendered":"\n<p>Pancreatic cancer is one of the most aggressive and deadly cancers, with less than 15% of patients surviving five years after diagnosis. Even when tumors appear operable, many patients relapse after surgery and chemotherapy. Drs. Rachael Safyan, E. Gabriela Chiorean,and Venu Pillarisetty aim to improve those odds by testing whether adding immunotherapy to current gold standard treatment can increase the chances of a cure.<\/p>\n\n\n\n<p>To date, few immunotherapies have been effective in patients with pancreatic cancer, in part because these tumors are especially skilled at evading the immune system by forming a barrier that keeps immune cells out. But, two immunotherapy drugs \u2013 cemiplimab (Libtayo<sup>\u00ae<\/sup>), which is approved to treat patients with basal cell carcinoma and cutaneous squamous cell carcinoma, and motixafortide (Aphexda<sup>\u00ae<\/sup>), which is approved to treat patients with multiple myeloma \u2013 may help break through that wall.&nbsp;<\/p>\n\n\n\n<p>This new clinical trial will test these two drugs in combination with a chemotherapy regimen called nalirifox (liposomal irinotecan [Onivyde\u00ae], 5 fluorouracil \/leucovorin, and oxaliplatin) given before surgery. The goal is to shrink tumors, improve surgical outcomes, and prevent relapse. This study represents a critical step toward making immunotherapy effective in one of cancer\u2019s most difficult frontiers.<\/p>\n\n\n\n<p>In addition to the University of Washington, clinical trial sites include the Fred Hutchinson Cancer Center and the University of Cincinnati.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Projects and Grants<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Randomized phase II study of neoadjuvant NALIRIFOX with and without PD1 and CXCR4 inhibition for potentially resectable pancreatic cancer<\/strong><\/h3>\n\n\n\n<h2 class=\"wp-block-heading\">Co-Investigators<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>E. Gabriela Chiorean, MD<\/li>\n\n\n\n<li>Venu Pillarisetty, MD<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Pancreatic cancer is one of the most aggressive and deadly cancers, with less than 15% of patients surviving five years after diagnosis. Even when tumors appear operable, many patients relapse after surgery [&hellip;]<\/p>\n","protected":false},"featured_media":35834,"template":"","tax_cancer_type":[355],"tax_grant_type":[725],"tax_award_year":[742],"tax_institutions":[496],"tax_location_states":[503],"class_list":["post-35828","cri_scientists","type-cri_scientists","status-publish","has-post-thumbnail","hentry"],"acf":{"scientist_subhead":"CRI Clinical Innovator","quote":"","scientist_last_name":"Bhardwaj","show_on_landing":false,"scientist_publish_until":"20280831"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Rachael Safyan, MD - Cancer Research Institute<\/title>\n<meta name=\"description\" content=\"Pancreatic cancer is one of the most aggressive and deadly cancers, with less than 15% of patients surviving five years after diagnosis. Even when tumors appear operable, many patients relapse after surgery and chemotherapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/rachael-safyan-md\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rachael Safyan, MD - Cancer Research Institute\" \/>\n<meta property=\"og:description\" content=\"Pancreatic cancer is one of the most aggressive and deadly cancers, with less than 15% of patients surviving five years after diagnosis. Even when tumors appear operable, many patients relapse after surgery and chemotherapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/rachael-safyan-md\" \/>\n<meta property=\"og:site_name\" content=\"Cancer Research Institute\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-06T21:33:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/08\/Rachael-Safyan-MD-1-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1707\" \/>\n\t<meta property=\"og:image:height\" content=\"2560\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/rachael-safyan-md\",\"url\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/rachael-safyan-md\",\"name\":\"Rachael Safyan, MD - Cancer Research Institute\",\"isPartOf\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/rachael-safyan-md#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/rachael-safyan-md#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/08\/Rachael-Safyan-MD-1-scaled.jpg\",\"datePublished\":\"2025-08-06T21:33:35+00:00\",\"dateModified\":\"2025-08-06T21:33:42+00:00\",\"description\":\"Pancreatic cancer is one of the most aggressive and deadly cancers, with less than 15% of patients surviving five years after diagnosis. Even when tumors appear operable, many patients relapse after surgery and chemotherapy.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/rachael-safyan-md#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/rachael-safyan-md\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/rachael-safyan-md#primaryimage\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/08\/Rachael-Safyan-MD-1-scaled.jpg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/08\/Rachael-Safyan-MD-1-scaled.jpg\",\"width\":1707,\"height\":2560},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/rachael-safyan-md#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.cancerresearch.org\/es\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rachael Safyan, MD\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.cancerresearch.org\/#website\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"name\":\"Cancer Research Institute\",\"description\":\"For a World Immune to Cancer\",\"publisher\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.cancerresearch.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.cancerresearch.org\/#organization\",\"name\":\"Cancer Research Institute\",\"url\":\"https:\/\/www.cancerresearch.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"contentUrl\":\"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg\",\"width\":156,\"height\":53,\"caption\":\"Cancer Research Institute\"},\"image\":{\"@id\":\"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rachael Safyan, MD - Cancer Research Institute","description":"Pancreatic cancer is one of the most aggressive and deadly cancers, with less than 15% of patients surviving five years after diagnosis. Even when tumors appear operable, many patients relapse after surgery and chemotherapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/rachael-safyan-md","og_locale":"es_ES","og_type":"article","og_title":"Rachael Safyan, MD - Cancer Research Institute","og_description":"Pancreatic cancer is one of the most aggressive and deadly cancers, with less than 15% of patients surviving five years after diagnosis. Even when tumors appear operable, many patients relapse after surgery and chemotherapy.","og_url":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/rachael-safyan-md","og_site_name":"Cancer Research Institute","article_modified_time":"2025-08-06T21:33:42+00:00","og_image":[{"width":1707,"height":2560,"url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/08\/Rachael-Safyan-MD-1-scaled.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/rachael-safyan-md","url":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/rachael-safyan-md","name":"Rachael Safyan, MD - Cancer Research Institute","isPartOf":{"@id":"https:\/\/www.cancerresearch.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/rachael-safyan-md#primaryimage"},"image":{"@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/rachael-safyan-md#primaryimage"},"thumbnailUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/08\/Rachael-Safyan-MD-1-scaled.jpg","datePublished":"2025-08-06T21:33:35+00:00","dateModified":"2025-08-06T21:33:42+00:00","description":"Pancreatic cancer is one of the most aggressive and deadly cancers, with less than 15% of patients surviving five years after diagnosis. Even when tumors appear operable, many patients relapse after surgery and chemotherapy.","breadcrumb":{"@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/rachael-safyan-md#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cancerresearch.org\/cri-funded-scientists\/rachael-safyan-md"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/rachael-safyan-md#primaryimage","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/08\/Rachael-Safyan-MD-1-scaled.jpg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/08\/Rachael-Safyan-MD-1-scaled.jpg","width":1707,"height":2560},{"@type":"BreadcrumbList","@id":"https:\/\/www.cancerresearch.org\/cri-funded-scientists\/rachael-safyan-md#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cancerresearch.org\/es"},{"@type":"ListItem","position":2,"name":"Rachael Safyan, MD"}]},{"@type":"WebSite","@id":"https:\/\/www.cancerresearch.org\/#website","url":"https:\/\/www.cancerresearch.org\/","name":"Cancer Research Institute","description":"For a World Immune to Cancer","publisher":{"@id":"https:\/\/www.cancerresearch.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cancerresearch.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.cancerresearch.org\/#organization","name":"Cancer Research Institute","url":"https:\/\/www.cancerresearch.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/","url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","contentUrl":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/05\/logo-gradient.svg","width":156,"height":53,"caption":"Cancer Research Institute"},"image":{"@id":"https:\/\/www.cancerresearch.org\/#\/schema\/logo\/image\/"}}]}},"fimg_url":"https:\/\/www.cancerresearch.org\/wp-content\/uploads\/2025\/08\/Rachael-Safyan-MD-1-scaled.jpg","_links":{"self":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_scientists\/35828","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/cri_scientists"}],"about":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/types\/cri_scientists"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media\/35834"}],"wp:attachment":[{"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/media?parent=35828"}],"wp:term":[{"taxonomy":"tax_cancer_type","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_cancer_type?post=35828"},{"taxonomy":"tax_grant_type","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_grant_type?post=35828"},{"taxonomy":"tax_award_year","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_award_year?post=35828"},{"taxonomy":"tax_institutions","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_institutions?post=35828"},{"taxonomy":"tax_location_states","embeddable":true,"href":"https:\/\/www.cancerresearch.org\/es\/wp-json\/wp\/v2\/tax_location_states?post=35828"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}